Clinical Study
Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma
Table 1
Patients demographics.
| | Phase Ia | Phase Ib |
| Age, mean (min, max) | 64.2 (45, 83) | 64.7 (54, 80) | Male | 10 (76.9%) | 5 (71.4%) | Caucasian | 13 (100%) | 7 (100%) | Stage IV | 13 (100%) | 6 (85.7%) | Prior therapies | | | Chemotherapy | 11 (84.6%) | 3 (42.9%) | Immunotherapy | 9 (69.2%) | 6 (85.7%) | Radiotherapy | 3 (23.1%) | 4 (57.1%) | Surgery | 13 (100%) | 7 (100%) |
|
|